Advances in Immunological Therapeutics – Vol 1 (2023 advances)
- HMX
Group Enrollment Option A program that is a popular choice for organizations and institutions to purchase in bulk.
Learn about innovative immunological therapies approved by the FDA from 2021 through 2023 for the treatment of a number of chronic diseases.
- Online; Self-Paced
Enroll by Friday and get access to course materials the following Wednesday to complete at your own pace.
Certificate
Earn a short course certificate of completion when you finish all coursework within 8 weeks.
3-4 Hours
Most people can expect to complete short courses in 3-4 hours.
On This Page
Overview
Over the past few decades, it has become increasingly clear that a weakened or overactive immune response underlies the development of many chronic conditions, ranging from autoimmune diseases to cancer. Advances in our understanding of our immune system has led to the development of therapies that modulate immune responses to treat various conditions with an immunological basis.
In this HMX short course, you will learn from leading Harvard Medical School faculty about cutting-edge immunological therapeutics that have been recently approved by the FDA in 2023 for the treatment of a number of different chronic diseases. Learning how new therapies enhance or suppress our immune system is essential for anyone looking to develop or apply new immunomodulatory therapies to treat disease.
Participant Types
Researchers in biomedicine and pharmacology; clinicians and other medical professionals; professionals in managerial roles in health care and the pharmaceutical or a related industry
About the Course
HMX short courses feature targeted lessons on the latest medical science topics and advancements. Stay up-to-date on essential knowledge in both artificial intelligence (AI) and immunology by exploring these specialized topics in a shorter format.
Who Should Apply
This course will benefit researchers in biomedicine and pharmacology who are keen to learn about the latest developments in immunological treatments with a strong emphasis on understanding the pathology of the diseases they are designed to treat; clinicians and other medical professionals seeking a firm understanding of the mechanisms of action of new immunological therapeutics; professionals in managerial roles in health care and the pharmaceutical industry who are interested in a well-structured overview of how different aspects of the immune system are being harnessed to develop drugs that treat inflammatory diseases and cancer.
Course Format
Most people can expect to spend 3-4 hours total on an HMX short course. In order to be considered for a short course certificate of completion, you must complete your coursework within eight weeks.
Group Enrollments
HMX courses are ideal for organizations looking to train teams or larger groups. Group pricing is available, making it a cost-effective investment in team development.
Faculty
HMX courses are led by Harvard Medical School faculty, working in collaboration with a multi-disciplinary team of experts in biomedical visualization, assessment, and the science of learning to create a unique learning experience that will stay with you.
Carlos Donado
PhD
- Instructor in Medicine, Harvard Medical School / Immunologist, Brigham and Women’s Hospital
- Immunology Curriculum Fellow, HMX
Shiv Pillai
MD, PhD
- Professor of Medicine and Health Sciences and Technology, Harvard Medical School
Andrew Lichtman
MD, PhD
- Professor of Pathology, Harvard Medical School
- Pathologist, Brigham and Women's Hospital
Request Information
Interested in learning more about this program? Sign up for details.